OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CSN$323.5058

Chesnara PLC

Life & Health InsuranceVerified

Chesnara's capital structure is characterized by a high price-to-book ratio of 132.65, indicating a significant premium over its book value. The company's liquidity position is assessed as medium, with negative net cash after subtracting total debt. Free cash flow is negative at -35 million GBP, and operating cash flow is also negative at -219.8 million GBP, suggesting cash flow challenges. Profitability metrics show a return on equity of -1.85% and a return on assets of -0.07%, both well below the industry norms for a life and health insurance company. Net income is negative at -10.4 million GBP, and operating income is 18.8 million GBP, indicating operational inefficiencies and potential underperformance relative to industry peers. Geographically, Chesnara's revenue concentration is not disclosed in the available data, but the company's exposure to the UK market is evident given the GBP-based financials. Segment-wise, the company operates as a single entity in the life and health insurance space, with no disclosed diversification across product lines or geographic regions. Growth trajectory is mixed, with a current fiscal year outlook showing a negative net income and a lack of clear guidance for the next fiscal year. The company's operating income has declined, and the negative free cash flow suggests a lack of internal funding for growth initiatives. Analysts have a cautiously optimistic outlook, with a mean price target of 337.25 GBP and a median of 334.50 GBP. Risk factors include liquidity constraints and the potential for further dilution, although the risk of dilution is currently assessed as low. The company's debt-to-equity ratio of 0.36 is relatively low, but the negative net cash position raises concerns about short-term liquidity. No recent filings or transcripts are available to provide additional context on strategic or operational developments. Recent events and filings do not provide additional insights into Chesnara's strategic direction or operational performance. The company's financial statements and analyst estimates are the primary sources of information, with no recent material events disclosed in the available data.

30-day price · CSN+26.30 (+9.0%)
Low$284.50High$327.00Close$319.50As of16 May, 00:00 UTC
Profile
CompanyChesnara PLC
TickerCSN.L
SectorFinancials
BusinessInsurance
Industry groupInsurance
IndustryLife & Health Insurance
AI analysis

Business. Chesnara PLC provides life and health insurance products and services, generating revenue primarily through premium income and investment returns on its insurance liabilities.

Classification. Chesnara is classified under the Life & Health Insurance industry within the Financials sector, with a high confidence level of 0.92 based on verified market data.

Chesnara's capital structure is characterized by a high price-to-book ratio of 132.65, indicating a significant premium over its book value. The company's liquidity position is assessed as medium, with negative net cash after subtracting total debt. Free cash flow is negative at -35 million GBP, and operating cash flow is also negative at -219.8 million GBP, suggesting cash flow challenges. Profitability metrics show a return on equity of -1.85% and a return on assets of -0.07%, both well below the industry norms for a life and health insurance company. Net income is negative at -10.4 million GBP, and operating income is 18.8 million GBP, indicating operational inefficiencies and potential underperformance relative to industry peers. Geographically, Chesnara's revenue concentration is not disclosed in the available data, but the company's exposure to the UK market is evident given the GBP-based financials. Segment-wise, the company operates as a single entity in the life and health insurance space, with no disclosed diversification across product lines or geographic regions. Growth trajectory is mixed, with a current fiscal year outlook showing a negative net income and a lack of clear guidance for the next fiscal year. The company's operating income has declined, and the negative free cash flow suggests a lack of internal funding for growth initiatives. Analysts have a cautiously optimistic outlook, with a mean price target of 337.25 GBP and a median of 334.50 GBP. Risk factors include liquidity constraints and the potential for further dilution, although the risk of dilution is currently assessed as low. The company's debt-to-equity ratio of 0.36 is relatively low, but the negative net cash position raises concerns about short-term liquidity. No recent filings or transcripts are available to provide additional context on strategic or operational developments. Recent events and filings do not provide additional insights into Chesnara's strategic direction or operational performance. The company's financial statements and analyst estimates are the primary sources of information, with no recent material events disclosed in the available data.
Key takeaways
  • Chesnara has a high price-to-book ratio of 132.65, indicating a significant premium over its book value.
  • The company's return on equity is -1.85%, and return on assets is -0.07%, both below industry norms.
  • Chesnara's liquidity position is medium, with negative net cash after subtracting total debt.
  • Analysts have a cautiously optimistic outlook, with a mean price target of 337.25 GBP.
  • The company's growth trajectory is mixed, with a negative net income and lack of clear guidance for the next fiscal year.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyGBP
Revenue
Gross profit
Operating income$18.8M
Net income-$10.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$219.8M
CapEx-$900.0k
Free cash flow-$35.0M
Total assets$14.58B
Total liabilities$14.01B
Total equity$563.3M
Cash & equivalents$145.3M
Long-term debt$205.3M
Valuation
Market price$323.50
Market cap$74.72B
Enterprise value$74.78B
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income3977.7
EV/OCF
P/B132.7
P/Tangible book132.7
Tangible book$563.3M
Net cash-$60.0M
Current ratio
Debt/Equity0.4
ROA-0.1%
ROE-1.8%
Cash conversion21.1%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Life & Health Insurance · cohort 15 companies
MetricCSNActivity
Op margin12.3% medp25 5.6% · p75 21.6%
Net margin2.9% medp25 0.5% · p75 10.1%
Gross margin28.2% medp25 13.4% · p75 30.5%
CapEx / revenue-2.1% medp25 -8.2% · p75 -1.2%
Debt / equity36.0%27.5% medp25 4.7% · p75 66.5%above median
Observations
IR observations
Mean price target337.25 GBP
Median price target334.50 GBP
High price target360.00 GBP
Low price target320.00 GBP
Mean recommendation1.80 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count2.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.19 GBP
Last actual EPS-0.05 GBP
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 00:43 UTC#6c95d57b
Market quoteclose GBP 322.00 · shares 0.23B diluted
no public URL
2026-05-16 00:44 UTC#64061153
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 17:15 UTCJob: a9322d55